MedTrace Logo

Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19

NCT04292340 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2020-03-03

No results posted yet for this study

Summary

There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma.The study is to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia.

Conditions

  • Coronavirus

Sponsors & Collaborators

  • Shanghai Public Health Clinical Center

    lead OTHER_GOV

Principal Investigators

  • Hongzhou Lu, Ph.D · Shanghai Public Health Clinical Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-07-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04292340 on ClinicalTrials.gov